Briacell Therap (NASDAQ:BCTX) Sees Large Growth in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 145,756 shares, an increase of 40.2% from the February 26th total of 103,944 shares. Based on an average daily trading volume, of 273,289 shares, the short-interest ratio is currently 0.5 days. Currently, 2.0% of the company’s stock are short sold.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new stake in Briacell Therap (NASDAQ:BCTX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Briacell Therap Price Performance

NASDAQ:BCTX opened at $3.75 on Friday. Briacell Therap has a 12 month low of $3.60 and a 12 month high of $98.20. The firm has a market capitalization of $27.19 million, a PE ratio of -0.16 and a beta of 1.46. The business’s fifty day moving average price is $4.17 and its 200 day moving average price is $7.87.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Briacell Therap will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.